Daewoong Enters P3 Trial for Nabota in China

Korea Biomedical Review reports Daewoong Pharmaceutical received approval from China Food and Drug Administration (CFDA) for its phase 3 clinical trial into nabota, its botulinum toxin.  The industry sponsor had to refile its clinical trial application (CTA) with an...

Pin It on Pinterest